skip to Main Content

Council of Academic Hospitals features WaveCheck technology and crowdfunding campaign

waveThe Council of Academic Hospitals of Ontario’s online magazine highlighted WaveCheck on February 3, 2014 as a more personalized approach to cancer treatments because of the technology’s ability to effectively monitor chemotherapy response.

WaveCheck’s technology, invented by Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre and Professor Michael C. Kolios of Ryerson University, allows women and men undergoing chemotherapy for breast cancer to know if their treatment is working at the beginning of treatment (within one to four weeks) rather than at the end of treatment (typically four to six months).

Here’s an excerpt from the article:

Breast cancer is the most common cancer among Canadian women, excluding non-melanoma skin cancers. It is the second leading cause of death from cancer in women in this country. The Canadian Cancer Society estimated that, in 2013, 65 Canadian women would be diagnosed with breast cancer every day, totaling 23,800 women a year; and 14 Canadian women would die from breast cancer every day, totaling 5,000 women a year. According to the Canadian Breast Cancer Foundation, one in nine Canadian women is expected to develop breast cancer during her lifetime; one in 29 will die from it.

Continue Reading

Stem Cell Therapeutics Merger, Technology Featured in Biotechnology Focus

Dr. Aaron Schimmer, University Health Network
Dr. Aaron Schimmer of the University Health Network discovered that Tigecycline was effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.

In a November 25 article in Biotechnology Focus magazine, author Shawn Lawrence highlights Stem Cell Therapeutics and Trillium Therapeutics Inc. coming together in a reverse merger that creates more opportunities to advance early-stage research.

The article profiles Dr. Aaron Schimmer and his discovery that Tigecycline is effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.

Here’s a quote from Lawrence’s article:

“Dr. Schimmer’s research is focused on drug repurposing – finding new indications for approved therapeutics. Focusing on established drugs with known safety profiles can significantly lower the risk in the drug development process, saving time and cost,” says Dr. Niclas Stiernholm, president and CEO of Stem Cell Therapeutics Corp.”

Continue Reading

CAMH researcher’s leading-edge therapy targets brain chemistry of addiction

CAMH and MaRS Innovation partner on innovative approach to nicotine addiction

Centre for Addiction and Mental Health (CAMH) LogoTORONTO (Dec. 17, 2009) — Grappling with nicotine addiction is never easy, but a new drug therapy – developed by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) – brings promise to one of our great public health challenges.

The experimental medication in development at Dr. Liu’s lab targets the brain chemistry associated with addiction by disrupting a specific receptor-receptor interaction.

Proof-of-concept data demonstrate that this therapy decreases addictive behavior associated with nicotine and alcohol in preclinical models.

Continue Reading
Back To Top